Posted: Friday, September 13, 2019
Bernardo H.L. Goulart, MD, of Seattle Cancer Care Alliance, offers practical suggestions for bringing up and discussing the difficult subject of how cost can affect a patient’s outcome for treatment of EGFR- or ALK-positive non–small cell lung cancer.